Cargando…
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (4...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360633/ https://www.ncbi.nlm.nih.gov/pubmed/16868545 http://dx.doi.org/10.1038/sj.bjc.6603270 |
_version_ | 1782153097435414528 |
---|---|
author | Blackstock, A W Mornex, F Partensky, C Descos, L Case, L D Melin, S A Levine, E A Mishra, G Limentani, S A Kachnic, L A Tepper, J E |
author_facet | Blackstock, A W Mornex, F Partensky, C Descos, L Case, L D Melin, S A Levine, E A Mishra, G Limentani, S A Kachnic, L A Tepper, J E |
author_sort | Blackstock, A W |
collection | PubMed |
description | The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m(−2)) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5½ weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000 mg m(−2)) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35–79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control. |
format | Text |
id | pubmed-2360633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23606332009-09-10 Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study Blackstock, A W Mornex, F Partensky, C Descos, L Case, L D Melin, S A Levine, E A Mishra, G Limentani, S A Kachnic, L A Tepper, J E Br J Cancer Clinical Study The safety and efficacy of gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with resected pancreatic cancer was determined. Patients with resected adenocarcinoma of the pancreas were treated with intravenous gemcitabine administered twice-weekly (40 mg m(−2)) for 5 weeks concurrent with upper abdominal radiation (50.4 Gy in 5½ weeks). At the completion of the chemoradiation, patients without disease progression were given gemcitabine (1000 mg m(−2)) weekly for two cycles. Each cycle consisted of 3 weeks of treatment followed by 1 week without treatment. Forty-seven patients were entered, 46 of whom are included in this analysis. Characteristics: median age 61 years (range 35–79); 24 females (58%); 73% stage T3/T4; and 70% lymph node positive. Grade III/IV gastrointestinal or haematologic toxicities were infrequent. The median survival was 18.3 months, while the median time to disease recurrence was 10.3 months. Twenty-four percent of patients were alive at 3 years. Only six of 34 patients with progression experienced local regional relapse as a component of the first site of failure. These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control. Nature Publishing Group 2006-08-07 2006-07-25 /pmc/articles/PMC2360633/ /pubmed/16868545 http://dx.doi.org/10.1038/sj.bjc.6603270 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Blackstock, A W Mornex, F Partensky, C Descos, L Case, L D Melin, S A Levine, E A Mishra, G Limentani, S A Kachnic, L A Tepper, J E Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study |
title | Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study |
title_full | Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study |
title_fullStr | Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study |
title_full_unstemmed | Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study |
title_short | Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study |
title_sort | adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase ii study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360633/ https://www.ncbi.nlm.nih.gov/pubmed/16868545 http://dx.doi.org/10.1038/sj.bjc.6603270 |
work_keys_str_mv | AT blackstockaw adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT mornexf adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT partenskyc adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT descosl adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT caseld adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT melinsa adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT levineea adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT mishrag adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT limentanisa adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT kachnicla adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy AT tepperje adjuvantgemcitabineandconcurrentradiationforpatientswithresectedpancreaticcanceraphaseiistudy |